The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

(2012) Naomi Schlesinger et al.   ANNALS OF THE RHEUMATIC DISEASES

One Target—Two Different Binding Modes: Structural Insights into Gevokizumab and Canakinumab Interactions to Interleukin-1β

(2012) Michaela Blech et al.   JOURNAL OF MOLECULAR BIOLOGY

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

(2012) Charles A. Dinarello et al.   NATURE REVIEWS DRUG DISCOVERY

Structure of the activating IL-1 receptor signaling complex

(2012) Christoph Thomas et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

(2012) Nicolino Ruperto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overview of theCCP4 suite and current developments

(2011) Martyn D. Winn et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Structural insights into the assembly and activation of IL-1β with its receptors

(2010) Dongli Wang et al.   NATURE IMMUNOLOGY

Immunological and Inflammatory Functions of the Interleukin-1 Family

(2009) Charles A. Dinarello   Annual Review of Immunology

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

(2009) Helen J. Lachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

(2008) Rieke Alten et al.   ARTHRITIS RESEARCH & THERAPY